In order for a drug to get approved by the FDA for market in the USA, the sponsor must ultimately demonstrate the drug has: 1) a predictable exposure profile with [….]
BIOF 084 | Pharmacometric Dose-Response Analyses in Clinical Trials Using R
Washington DC’s Danaher To Acquire Aldevron
Danaher Corporation (NYSE: DHR) (the “Company”) announced today that Danaher has entered into a definitive agreement to acquire privately-held Aldevron, for a cash purchase price of approximately $9.6 billion. Danaher expects to finance the acquisition using cash on hand and/or proceeds from the issuance of commercial paper.